InvestSMART

Neurotech International Limited (ASX:NTI)

ALERT: Price-sensitive ASX Announcement for NTI
Current share price for NTI : $0.017 0 (0%)+
Announcement
Release
28 Oct 2025 11:13AM
Price at Release
$0.017
Full Release
download
Summary
Neurotech International Limited reported its quarterly activities for the period ending 30 September 2025. Key updates include the initiation of the NTI164 Authorised Prescriber program in Australia to expand access to their investigational therapy, NTI164, for paediatric neurological disorders. The company also received the US FDA Rare Paediatric Disease Designation for NTI164 for Rett Syndrome, enhancing its regulatory position. Financially, Neurotech reported total operating cash outflows of approximately $1.2 million, with research and development costs constituting a significant portion. The company anticipates receiving $4.7 million from the R&D Tax Incentive in the subsequent quarter. Cash and cash equivalents at the end of the quarter were approximately $1.7 million, with payments to related parties totaling $127,000.
Key Points
  • Quarterly activities report for period ending 30 September 2025.
  • Initiated NTI164 Authorised Prescriber program in Australia.
  • Received US FDA Rare Paediatric Disease Designation for NTI164.
  • Total operating cash outflows of ~$1.2 million.
  • Anticipated R&D Tax Incentive of ~$4.7 million next quarter.
  • End-of-quarter cash and cash equivalents of ~$1.7 million.
  • Payments to related parties totaled $127,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.